Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of fevipiprant added to existing asthma therapy in uncontrolled asthma (GINA steps 3–5)
2016-001560-11Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Fevipiprant plus existing asthma therapy with Placebo plus existing asthma therapy (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jan 2017; status: terminated.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-001560-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001560-11.